Is HRT still indicated for the primary prevention of osteoporosis?


Hormone Replacement Therapy: In most European countries, the actual Guideline on the Evaluation of New Medicinal Products in the Treatment of Primary Osteoporosis is incomplete in that, unlike the previous Note for Guidance on Postmenopausal Osteoporosis in Women (EMEA 2001 Guidance), it fails to address the prevention of osteoporosis indication.

Reprinted with permission of the International Society of Gynecological Endocrinology

1. Hormone Replacement Therapy (HRT) for Fracture Prevention

Hormone Replacement Therapy: In most European countries, the actual Guideline on the Evaluation of New Medicinal Products in the Treatment of Primary Osteoporosis is incomplete in that, unlike the previous Note for Guidance on Postmenopausal Osteoporosis in Women (EMEA 2001 Guidance), it fails to address the prevention of osteoporosis indication.

Early prevention of osteoporosis is essential because the majority of fractures occur in the non-osteoporotic population. Furthermore, it is well known that individuals who had one osteoporotic fracture approximately double their risk to have another. Although treatment of osteoporosis can reduce the risk for a subsequent fracture, it cannot eliminate the excess risk. It is therefore essential to maintain bone architecture and quality as early as in the peri- and early postmenopause. Gynaecological endocrinologists are therefore greatly astonished that EMEA did not maintain the prevention of osteoporosis by estrogens as a first line medical intervention in women with an increased risk of osteoporosis and bone fractures in its latest recommendations.

It is well known that the first 5–10 years after menopause are associated with an accelerated rate of bone loss. Primary prevention of osteoporosis is directed at women identified as being at increased risk for the disease but without established disease. HRT has been shown to reduce postmenopausal bone loss and reduce fracture incidence in several RCT studies, including the PEPI trial (Writing group for the PEPI trial, 1996) and the HOPE trial (Lindsay et al., 2002) trial. More recently, the WHI trial, using a fixed combination of conjugated equine estrogens 0.625 mg and medroxyprogesterone acetate 2.5 mg, has shown that the resulting loss of bone architecture and quality this is preventable with hormone therapy and confirmed the fracture reduction efficacy of HRT, including hip and spine fractures (Cauley et al., 2003; Women’s Health Initiative Steering Committee, 2004). The WHI trial was of women aged between 50 and 80 years, who were not known to have increased fracture risk and who were supposed to be in general good health. In addition, the Women’s Health Initiative (Cauley et al., 2003) has demonstrated fracture prevention with hormone therapy in a non-osteoporotic population, too. This preventive effect is maintained: the PERF study (Bagger et al., 2004) demonstrated that administration of hormone therapy in early postmenopause offers a long-lasting benefit for the prevention of postmenopausal bone loss and osteoporotic fracture. Lower doses than previously thought necessary are now proving effective (Lees and Stevenson, 2001; Lindsay et al., 2002; Ettinger et al., 2004, Greenwald et al., 2005), and a very low dose estrogen product has recently been licensed for osteoporosis prevention by the US Food and Drugs Administration.

Hormone Replacement Therapy (HRT) is an effective treatment for prevention of osteoporotic fractures in women without established disease. These women tend to be younger, since older women have an increasing prevalence of osteoporosis as defined by bone density criteria (Kanis et al., 2001). Are younger women with osteopenia, rather than osteoporosis, at increased fracture risk? In the age group 50–80 years, around 36% of classical osteoporotic fractures occur in those below age 65 years (Singer et al., 1998; Kanis et al., 2004). In the UK, this amounts to over 100 000 fractures per year in women aged 50–65 years, over 9000 of which are hip fractures (Singer et al., 1998; Kanis et al., 2004;

There is no doubting the efficacy of HRT for the primary prevention of osteoporosis in post-menopausal women. Its current role in prevention of fractures seems best suited to those younger post-menopausal women with increased risk. In such a population, HRT use for osteoporosis prevention would be cost-effective (Lamy et al., 2003).

2. Alternatives to HRT:

The currently licensed alternatives to HRT for the secondary prevention of osteoporosis, preventing fractures in women with existing osteoporosis, include bisphosphonates, raloxifene, teriparatide, strontium ranelate, calcitonin and anabolic steroids. Calcium supplements and Vitamine D are licensed as an adjunct to therapy.

Of these, only bisphosphonates such as alendronate, risedronate, ibandronate and zoledronate have been shown to reduce the incidence of hip fractures, yet hip fracture is the most important osteoporotic fracture. However, both alendronate (Cummings et al., 1998) and risedronate (McClung et al., 2001) and other bisphoshonates have only been shown to prevent hip fracture in elderly women, mean age above 65 years, who already had osteoporosis, with bone density T-score in either hip or spine below –2.5, and in many cases had already sustained a fracture. Hip fractures occur most commonly in elderly women. However, bisphosphonates have not been shown in prospective studies to prevent hip fractures in younger women with increased risk rather than established disease. Furthermore, there are no data are available in precocious and in early menopause or in longstanding amenorrhea. However, today, there is an agreement that bisphosphonate use is more appropriate in asymptomatic elderly women being 10 or more years after their menopause than HRT regimens.

SERMs (selective estrogen receptor modulators) SERMs are licensed for the prevention and treatment of spinal osteoporosis in postmenopausal women. They have not been shown to reduce hip fracture risk. There is good evidence (level 1) for a reduction in estrogen receptor-positive breast cancers in users of SERMs. Therefore, there is an indication for SERMs in women with an increased risk for breast cancer. Currently available SERMs are not able to relieve climacteric symptoms in early postmenopausal women and may make them worse. SERMs have the same thromboembolic risk as per-oral HRT.

3. Main non-skeletal benefits and riks for HRT

Climacteric syndrome: The uncontested main indication for HRT remains the relief of post-menopausal symptoms, which brings a major improvement in quality of life (Utian et al., 2001; Birkhuser et al., 2008; Pines et al, 2007 and 2008). No other therapy has proved to be more effective than HRT in this respect.

Cardiovascular risk: EMEA expressed concern because of a possible increase of the cardiovascular (CVD ) risk of HRT in December 2003, mainly based on the publication of the first analysis of the WHI data in the combined in the estrogen-only arm (Manson et al., 2003; The Women’ Health Initiative Steering Committee, 2004). In fact, the WHI study was not designed, and therefore was not powered, to investigate the consequences of hormone replacement therapy (HRT) in women below 60 years of age. Therefore, any attempt to present the results of the study as indicating that HRT may inflict damage to the heart in general is profoundly wrong and must be amended.

It should be noted that the recent final analysis of WHI data (Hsia et al., 2006), as well as the latest update of the results of the Nurses’ Health Study (Grodstein et al., 2006 and 2000) have uniformly shown that HRT, when started soon after the start of menopause, does not increase the risk of CVD but may even protect against myocardial infarction. The outcomes in the youngest cohort of the WHI study (age 50–59 years or within 10 years of menopause) confirms previous evidence regarding a favourable effects on cardiovascular risk factors, vascular structure and function in nonatherosclerotic vessels, a reduced insulin resistance and reduction in the risk of diabetes and the preventative benefit of HRT for CHD in the majority of pre-clinical and observational studies. Young healthy postmenopausal women can be started on HRT when clinically warranted without fear of increased cardiovascular disease risk.

Thromboembolism and Stroke: The risks of ET for venous thromboembolism have been overstated in the WHI (Cushman, 2004) for the younger study participants. The VTE risk was age-dependent and significantly higher in the older and in obese women (BMI>25). The same has been found for stroke (Lobo et al., 2007). As Canonico et al. (2007) have shown, there is no significantly increased venous thromboembolic risk in women with parenteral estrogen application. Women seeking HRT who have potential or confirmed risk factors for venous thromboembolism and stroke need individualized counselling; in these situations, transdermal HRT might be preferable to oral formulations.

Breast cancer risk: The intention to eliminate the use of HRT from the prevention of osteoporsis / osteoporotic fractures, as expressed e.g. by EMEA in December 2003, is largely the consequence of the believe that HRT should increase the risk of breast cancer, mainly deduced again from the first publications of the WHI data (Writing Group for the Women’s Health Initiative Investigators, 2002; Chlebowski et al., 2003). However, newer publications from the WHI are showing a quite different picture. Because of its inherent weaknesses, we believe that the MWS (Million Women Study Collaborators, 2003; an observational study and not an RCT) should not be used as part of an evidence base for HRT and should be discounted by regulatory authorities.

The new sub-analysis of the unopposed estrogen arm of the WHI study has modified further the original alarmist messages (Stefanic et al., 2006). The WHI study investigators have released the details of breast cancer and mammography screening data for 10,739 women with prior hysterectomy, who received either estrogen replacement treatment (ERT) or placebo for a mean follow-up of 7.1 years (Stefanic et al., 2006). Thirty per cent of the subjects were aged 50–59 years and 24% were 70–79 years old at study entry; over half had never taken ET prior to the study. The initial report on the estrogen-only arm (The Women’ Health Initiative Steering Committee, 2004) concluded that there was a non-significant (p < 0.06) decreased risk for breast cancer in ERT users, but subgroup analyses now reveal that first lifetime exposure to ET at the trial was associated with fewer breast cancer cases as compared to placebo (hazard ratio (HR), 0.76; 95% confidence interval (CI), 0.58–0.99; p < 0.05). On the other hand, mammographic breast density increased in ERT users, with 9.2% having abnormalities in the ET group vs. 5.5% in the placebo group at 1 year (p < 0.001) and a cumulative percentage of 36.2% and 28.1%, respectively, leading to more breast biopsies.

Overall, the WHI study is in line with older observational data (Bush et al., 2001; Colditz et al., 1995) and carries the message that ERT for postmenopausal women does not increase the risk of breast cancer for at least up to 7 years. The incidence of diagnosis of breast cancer is increased with prolonged use of estrogen and, to a greater extent, with estrogen/progestogen treatment. Whether all progestogens are associated with an increase in breast cancer risk is currently unclear.

There is evidence that there may be some differences between the various estrogens, progestogens and progesterone in terms of their effect on the risk of breast cancer, but this requires more studies to confirm. Patients should be reassured that the possible risk of breast cancer after long-term HRT use (> 7 years in the WHI) is small and is comparable to the risk of a 1-year delay in menopause. Breast cancer risk is influenced by the total duration of exposure to endogenous and exogenous estrogens and progestogens. Some progestogens may increase the estrogen-dependent proliferation of mammary tissue. The WHI found no increase in breast cancer risk for duration of 7 years in participants with no prior use of HRT (Anderson et al, 2006).

In conclusion, young postmenopausal women starting on combined HRT for the first time should be advised that breast cancer risks do not appear to increase in the first 7 years of usage. Hysterectomized women on unopposed estrogen are not at increased risk of breast cancer and some may even have a small reduction in risk.

HRT and total mortality: There is no increase in total all-cause mortality in women using HRT (Salpeter et al., 2004), as might be the case if there were a significant increase in the risk of cardiovascular disease and breast cancer. In contrast, in younger women (50-60 years, or starting HRT less than 10 years after menopause), a recent metaanalysis suggests a significantly decreased risk of all-cause mortality. This supports the ‘window of opportunity’ theory where early use of HRT is associated with preventative cardiovascular benefits and is in agreement with the latest data from both the WHI and the Nurses’ Health Study.

4. Conclusions

Once again, it is apparent that the alarmist reports that spread worldwide when the first results of the WHI study were published in 2002 were unjustified based on the more recent further analyses, particularly in peri- and early postmenopausal women. It is very regrettable that, as a result, so many women and their medical advisors have lost confidence in the merits of HT, which will now be difficult to redress. Nevertheless, they should be reassured that, once recommended for an approved indication, with correct timing and after proper individual considerations, ERT/HRT is an effective therapy which may even have some extra benefits (cardiac, metabolic) in certain subgroups of women, for the period of time investigated in the WHI study. The risks of ERT/HRT have been overstated. Lower or ultra-low dosages of ERT/HRT may have an even better safety profile.

Finally, HRT is less expensive than any of the alternatives, and thus its use for primary prevention should be actively encouraged targeting women in their early postmenopause at high risk for fracture, such as those with osteopenia, with a family history of hip fracture, with a low body mass index or with a history of corticosteroid use. Bisphosphonates may be the more cost-effective intervention for elderly osteoporotic women. However, new data from a long-term prospective study suggest that even limited HRT use in women during early menopause may result in fracture reduction later (Bagger et al., 2004). A recent analysis of the WHI study data also showed that overall fracture benefit was maintained 16 months after discontinuation of estrogen plus progestogen (Jackson et al., 2004). Both these findings need to be confirmed.

With regard to safety issues, some regulatory authorities may have misinterpreted the new data from the recent studies such as the WHI.

HRT should be started with the lowest appropriate dose and increased if necessary.

Although low and ultra-low doses have been shown to be effective for menopause symptom relief data on reduction of fracture risk are missing. Women with premature ovarian failure generally require higher doses of HRT than those conventionally used in peri- and postmenopausal women. Arbitrary limitations on duration of therapy should be avoided. Benefits, risks and patient preferences should be discussed at least annually. Counselling should include discussion of benefits and risks in terms of absolute numbers of events rather than percentage changes.

In conclusion, HRT should be considered a first-line option for the primary prevention of osteoporosis-related fracture in precocious menopause even if asymptomatic. In the absence of data for the efficacy and safety of alternative preparations, HRT should be recommended in postmenopausal women at risk of osteoporosis-related fractures below the age of 60 as a first-line therapy. It should also be available to those older women with increased risk who either have persisting menopausal symptoms or who make an informed choice to use it.


© International Society of Gynecological Endocrinology - n. 30/2 February 2009


Prof. M. Birkhäuser

President of the Swiss Society against Osteoporosis

Founding Honorary President of EMAS

Gartenstrasse 67

CH-4052 Basel



Anderson GL, Chlebowski RT, Rossouw J, et al. Prior hormone therapy and breast cancer risk in the Women’s Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55: 103–15

Bagger YZ, Tankó LB, Alexandersen P, Hansen HB, Møllgaard A, Ravn P, Qvist P, Kanis JA and Christiansen C (2004). Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 34,728–735.

Birkhaeuser MH (Chair), Switzerland; Secretary: N. Panay, UK; D. F. Archer, USA; D. Barlow, UK; H. Burger, Australia; M. Gambacciani, Italy; S. Goldstein, USA; J. A. Pinkerton, USA; D. W. Sturdee, UK (Updated Recommendations Group) : Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. CLIMACTERIC 2008;11:108–123

Bush TL, Whiteman M and Flaws JA (2001). Hormone Replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 98,498–508.

Canonico M, Plu-Bureau G, Conard J, et al. Hormone therapy and venous thromboembolism among postmenopausal women. Circulation 2007;115:840–5

Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J et al. (2003). Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women’s Health Initiative randomized trial. J Am Med Assoc 290,1729–1738.

Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA et al. (2003). Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. J Am Med Assoc 289,3243–3253.

Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B and Speizer FE (1995). The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332,1589–1593.

Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC et al. (1998). Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. J Am Med Assoc 280,2077–2082.

Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S and Rosendaal FR (2004). Estrogen plus progestin and risk of venous thrombosis. J Am Med Assoc 292,1573–1580.

Ettinger B, Ensrud KE, Wallace R, Johnson KC, Cummings SR, Yankov V, Vittinghoff E and Grady D (2004). Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 104,443–451.

Greenwald MW, Gluck OS, Lang E, Rakov V. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects. Menopause 2005;12:741–8

Grodstein F, Manson JE, Stampfer MJ (2006). Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women’s Health 15:35–44

Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE and Stampfer MJ (2000). A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 133,933–941.

Hsia J, Langer RD, Manson JE, et al. (2006). Conjugated equine estrogens and coronary heart disease. The Women’s Health Initiative. Arch Intern Med 166:357–65

Jackson RD, Watts NB, Caralis P, Cauley A, Chen Z, Greep N, LaCroix AZ, Lewis CE, Mouton CP, Neuner JM et al. (2004). Fracture risk after estrogen plus progestin discontinuation: The Women’s Health Initiative. J Bone Miner Res S27 [Abstract 1100].

Kanis JA, Johnell O, Oden A, Dawson A, De Laet C and Jonsson B (2001). Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12,989–995.

Kanis JA, Johnell O, Oden A, De Laet C and Malstrom D (2004). Epidemiology of osteoporosis and fracture in men. Calcif Tissue Int 75,90–99.

Lamy O, Krieg MA, Burckhardt B and Wasserfallen JB (2003). An economic analysis of hormone replacement therapy for the prevention of fracture in young postmenopausal women. Expert Opin Pharmacother 4,1479–1488.

Lees B and Stevenson JC (2001). The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17-beta and dydrogesterone. Osteoporos Int 12,251–258.

Lindsay R, Gallagher JC, Kleerekoper M and Pickar JH (2002). Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. J Am Med Assoc 287,2668–2676.

Lobo RA. Menopause and stroke and the effects of hormone therapy. Climacteric 2007;10(Suppl 2): 27–31

Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R et al. (2003). Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349,523–534.

McClung MR, Geusens P, Millar PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R et al. (2001). Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344,333–340.

Million Women Study Collaborators (2003). Breast cancer and hormonereplacement therapy in the Million Women Study. Lancet 362,419–427.

Pines Amos (President), David W. Sturdee (General Secretary), Martin H. Birkhaeuser (Treasurer), Hermann P. G. Schneider, Marco Gambacciani and Nick Panay. Issued on behalf of the Board of the International Menopause Society. IMS Updated Recommendations on postmenopausal hormone therapy. CLIMACTERIC 2007;10:181–194

Pines A., D. W. Sturdee; M. H. Birkhäuser; T. de Villiers; F. Naftolin; A. Gompel; R. Farmer; D. Barlow; D. Tan; P. Maki; R. Lobo; H. Hodis et al. on behalf of the International Menopause Society et al.HRT in the early menopause: scientific evidence and common perceptions. CLIMACTERIC 2008;11:267–272

Salpeter SR, Walsh JM, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004;19:791–804

Singer BR, McLauchlan GJ, Robinson CM and Christie J (1998). Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br 80, 243–248.

Stefanic ML, Anderson GL, Margolis KL, et al. (2006). Effects of conjugated equine oestrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295:1647–57

Women’ Health Initiative Steering Committee. (2004) Effects of conjugated estrogen on postmenopausal women with hysterectomy: the Women’ Health Initiative randomized controlled trial. JAMA 291:1701–12

Writing Group for the Women’s Health Initiative Investigators. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 288,321–333.

Writing group for the PEPI trial. (1996) Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 276: 1389-1396

Utian, WH, Shoupe D, Bachmann G, Pinkerton JH, Pickar JH.(2001). Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated estrogens and medroxyprogesterone acetate. Fertility and Sterility 75:1065-1079

Related Videos
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit:
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit:
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit:
Navigating vasomotor symptoms in breast cancer patients | Image Credit:
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit:
Hot flashes poorly impact sleep quality | Image Credit:
How to manage bone health in midlife women | Image Credit: -
Mary Jane Minkin, MD, discusses The Menopause Society 2023 Annual Meeting | Image Credit: Yale School of Medicine
Highlights from The Menopause Society 2023 Annual Meeting  | Image Credit:
How fezolinetant changes management of hot flashes | Image Credit:
Related Content
© 2024 MJH Life Sciences

All rights reserved.